Development and validation of a bioanalytical method to quantitate enzalutamide and its active metabolite N-desmethylenzalutamide in human plasma: application to clinical management of metastatic castration-resistant prostate cancer patients

BACKGROUND: Enzalutamide is a potent androgen-signaling receptor inhibitor and is licensed for the treatment of metastatic castration-resistant prostate cancer. N-desmethylenzalutamide is the active metabolite of enzalutamide. A method to quantitate enzalutamide and its active metabolite was develop...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ther Drug Monit
Main Authors: Benoist, Guillemette E, van der Meulen, Eric, van Oort, Inge M, Beumer, Jan Hendrik, Somford, Diederik M, Schalken, Jack A, Burger, David M, van Erp, Nielka P
Formato: Artigo
Idioma:Inglês
Publicado: 2018
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6085835/
https://ncbi.nlm.nih.gov/pubmed/29419723
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FTD.0000000000000484
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares